Clinical trial Recruiting at 1 site Interventional Ages 18 and up Men only

Financial and counseling support for transgender women to improve health services access

Official title: Economic Navigation and Strengthening to Research Unrestricted Services for Transgender Women (ENTRUST)

Run by University of Central Florida · NCT06202898 · Data updated 2026-11-12

This study tests whether financial help and personalized counseling can make it easier for transgender women to access substance use services and HIV prevention methods like PrEP.

More AIDS trials

Quick facts

Study typeInterventional
Ages18 Years and up
SexMen only
Enrollment110 (estimated)
SponsorUniversity of Central Florida
Academic / other
Locations1 site (Orlando, Florida)
StatusRecruiting
StartedJuly 11, 2023
Main results expectedNovember 2025
Study endsJune 2027
Registry record updatedDecember 6, 2024
Trial IDNCT06202898 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are transgender women aged 18 and older who are not consistently using PrEP and can communicate in English or Spanish.

Probably not a fit

Patients with life-threatening substance use disorders or those unable to adhere to study procedures may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to explore how financial stabilization and tailored counseling can enhance the likelihood of transgender women accessing substance use services and pre-exposure prophylaxis (PrEP) if they are HIV-negative. It addresses the critical gap in understanding the relationship between substance use disorders and adherence to antiretroviral treatment (ART) among transgender women. By focusing on this vulnerable population, the study seeks to improve engagement in HIV prevention initiatives and treatment adherence, ultimately contributing to better health outcomes.

Why it matters

Potential benefit: If successful, this approach could significantly improve health service access and treatment adherence for transgender women, reducing HIV transmission rates.

How similar studies have gone: While there is limited literature specifically addressing this approach, similar studies have shown promise in improving health outcomes for marginalized populations.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Aged ≥18 years
* Male at birth
* Identify as a woman/transgender woman
* Should not be consistently using PrEP (less than four doses per week)
* Should not have any known allergy or adverse reaction to PrEP or the active drug tenofovir in ART. One of the goals of the study is to move more people into a PrEP program
* Be able to speak and understand spoken English and/or Spanish (including persons who cannot read or write)
* Have a smart phone that can take pictures

Exclusion Criteria:

* Unwilling to adhere to study procedures
* Participation in an HIV vaccine trial
* Have a life-threatening SUD\*
* Any condition, that in the opinion of the study staff, would make participation in the study unsafe, or interfere with achieving the study objective such as medical conditions which prevents the use of PrEP
* Unable to provide consent

Where it's running

  • University of Central Florida
    Orlando, Florida, United States
    Recruiting

Study contacts

  • Principal investigator: Elena Cyrus, PhD — University of Central Florida
  • Study coordinator: Elena Cyrus, PhD
  • Email: elena.cyrus@ucf.edu
  • Phone: 4072661507

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.